Sign inCreate account

Report workspace tools

NCT06514560RECRUITINGanonymous

OPTImizing MIltefosine Treatment for Cutaneous LEISHmaniasis Patients

Sponsor

Source record

Institute of Tropical Medicine, Belgium

Phase

Source record

Observational

Modality

AI-normalized

small molecule

Target

AI-normalized

Cutaneous Leishmaniasis

Indication / condition

AI-normalized

Cutaneous Leishmaniases

Intervention

Source record

Miltefosine

Source & freshness

Source record

NCT ID

NCT06514560

Original source

ClinicalTrials.gov

Source last updated

Jul 23, 2024

Ingested at

May 23, 2026

Internal sync

Jun 05, 2026

Model version

trialsignal-ai-v1

Normalized confidence

88%

Validation status

validated

Open original registry record
View original source fields

NCT ID

NCT06514560

Title

OPTImizing MIltefosine Treatment for Cutaneous LEISHmaniasis Patients

Sponsor

Institute of Tropical Medicine, Belgium

Status

RECRUITING

Phase

Observational

Condition raw

Cutaneous Leishmaniases

Condition normalized

Cutaneous Leishmaniases

Modality raw

Cutaneous Leishmaniases

Modality normalized

small molecule

Target raw

Cutaneous Leishmaniasis

Target normalized

Cutaneous Leishmaniasis

Interventions

Miltefosine

Public preview

Source record

The OPTIMILEISH trial aims to optimize miltefosine treatment for cutaneous leishmaniasis (CL) patients, particularly focusing on dosing strategies for children and understanding parasite dynamics. The study is being conducted by the Institute of Tropical Medicine in collaboration with several Ethiopian and international institutions.

AI-generated analysis supports research triage only. Verify source records, publications, sponsor disclosures and IP databases before making diligence decisions. Model: trialsignal-ai-v1.

Report access

Create an account to unlock this report

Choose the access model that matches the job: one urgent report, reusable credits for project work, or unlimited monthly access with AI and folders.

Full protocol, outcomes, eligibility, contacts and results sections
Patent/IP landscape with verified records when available
Board-ready PDF export with source provenance
Save to folders and synthesize multiple assets in premium workspace
Create account
Sign in

Create a free account first, then unlock a single report, buy credits or subscribe.

TrialSignal

Clinical trial intelligence report

OPTImizing MIltefosine Treatment for Cutaneous LEISHmaniasis Patients

Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.

Generated

Jun 13, 2026

NCT ID

NCT06514560

Status

RECRUITING

Phase

Observational

Sponsor

Institute of Tropical Medicine, Belgium

Executive brief

Investment-Ready Snapshot

The OPTIMILEISH trial aims to optimize miltefosine treatment for cutaneous leishmaniasis (CL) patients, particularly focusing on dosing strategies for children and understanding parasite dynamics. The study is being conducted by the Institute of Tropical Medicine in collaboration with several Ethiopian and international institutions.

Source & freshness

Provenance

SourceClinicalTrials.gov
Source updatedJul 23, 2024
Internal syncJun 05, 2026
Model versiontrialsignal-ai-v1

https://clinicaltrials.gov/study/NCT06514560

Indication

Cutaneous Leishmaniases

Modality

small molecule

Target

Cutaneous Leishmaniasis

Intervention

Miltefosine

Source record

Protocol Description

Detailed source ingestion pending.

Source record

Outcome Measures

Detailed source ingestion pending.

Source record

Eligibility

Detailed source ingestion pending.

AI analysis

Known Results And Readout Context

Detailed source ingestion pending.

IP intelligence

Patent And IP Landscape

Detailed source ingestion pending.

Source record

Contacts

Detailed source ingestion pending.